Free shipping on all orders over $ 500

Pyridostigmine Bromide

Cat. No. M3393
Pyridostigmine Bromide Structure
Size Price Availability Quantity
500mg USD 55  USD55 In stock
1g USD 75  USD75 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Pyridostigmine Bromide (Mestinon) is a parasympathomimetic and a reversible cholinesterase inhibitor. Pyridostigmine Bromide inhibits acetylcholinesterase in the synaptic cleft, thus slowing down the hydrolysis of acetylcholine. It is a quaternary carbamate inhibitor of cholinesterase that does not cross the blood-brain barrier, and it is taken daily in anticipation of an attack, which carbamylates about 30% of peripheral cholinesterase enzyme. The carbamylated enzyme eventually regenerates by natural hydrolysis and excess ACh levels revert to normal.

Chemical Information
Molecular Weight 261.12
Formula C9H13BrN2O2
CAS Number 101-26-8
Form Solid
Solubility (25°C) DMSO 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Ioannis Partheniadis, et al. Monitoring the weight and dimensional expansion of pyridostigmine bromide tablets under dynamic vapor sorption and impact of deliquescence on tablet strength and drug release

[2] Paulo Jos Lorenzoni, et al. Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials

[3] Ramandeep Bansal, et al. Management of myasthenia gravis during pregnancy

[4] S R Schreglmann, et al. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial

[5] Barry J Gales, et al. Pyridostigmine in the treatment of orthostatic intolerance

Related AChR/AChE Products
Tacrine

Tacrine is a potent acetylcholinesterse (AChE) inhibitor (IC50=109 nM), also acting as a CYP1A2 substrate agent.

THRX-160209

THRX-160209 is a potent antagonist at the M(2) muscarinic acetylcholine (ACh) receptor subtype that was designed using a multivalent strategy, simultaneously targeting the orthosteric site and a nearby site known to bind allosteric ligands.

Catestatin

Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide.

α-Conotoxin MII

α-Conotoxin MII (α-CTxMII), a 16-amino acid peptide from the venom of the marine snail Conus magus, potently blocks nicotinic acetylcholine receptors (nAChRs) composed of α3β2 subunits, with an IC50 of 0.5 nM.

COG 133 TFA

COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide.

  Catalog
Abmole Inhibitor Catalog




Keywords: Pyridostigmine Bromide supplier, AChR/AChE, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.